Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial-Reference-Cited by-同舟云学术

Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial

Published:2024-03 Issue: Volume:69 Page:102447
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Shimoi Tatsunori^ORCID,Sunami Kuniko,Tahara Makoto,Nishiwaki Satoshi,Tanaka Shota,Baba Eishi,Kanai Masashi,Kinoshita Ichiro,Shirota Hidekazu,Hayashi Hideyuki,Nishida Naohiro,Kubo Toshio^ORCID,Mamesaya Nobuaki,Ando Yayoi,Okita Natsuko,Shibata Taro,Nakamura Kenichi,Yamamoto Noboru^ORCID

Funder

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Reference28 articles.

1. Clinical development of BRAF plus MEK inhibitor combinations;Subbiah;Trends Cancer,2020

2. Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy;Gouda;ESMO Open,2023

3. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma;Long;N Engl J Med,2014

4. BRAF mutation marks out specific subgroups of glioma;Chan;Glioma,2018

5. Integrated genomic characterization of papillary thyroid carcinoma;Cell,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine;Life;2024-09-10

2. Tumor-Agnostic Therapy—The Final Step Forward in the Cure for Human Neoplasms?;Cells;2024-06-20

3. Current and Future Therapeutic Targets for Directed Molecular Therapies in Cholangiocarcinoma;Cancers;2024-04-26